Registration effective
Open the filing on sec.gov
Lexaria Bioscience Corp. (LEXX)
Nasdaq: LEXX · Pharmaceutical Preparations · Kelowna, BC · filing with the SEC since 2006
The companyfiscal 2025, as filed
Revenue$705,923+52.0%
Net income-$11.9M-105.4%
Earnings per share$-0.66-40.4%
Operating cash flow-$10.5M-110.7%
Cash$1.8M-72.3%
Debtn/a
Shareholders’ equity$3.0M-62.8%
Shares, diluted18.0M+45.3%
Return on equity-398.1%
The recordfrom its filings
Filings in 202619
Newest filingOct 13 · EFFECT
Annual reportNov 28, 2025
Quarterly reportJul 13, 2026
Next report due10-K by Nov 29
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents grantedn/a
Filer categoryNon-accelerated filer<br>Smaller reporting company
Trailing twelve months to May 2026Revenue $194,000Net income -$7.7MCash from operations -$7.4Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Shelf offering
Open the filing on sec.gov
Shelf registration
Open the filing on sec.gov
Private placement notice
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Quarterly report
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.